Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma

NCT02599402 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

533

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb